Biomarkers and treatment characteristics in metastatic colorectal cancer RASwt patients in Latin America




Juan O’Connor, Gastrointestinal Unit, Instituto Alexander Fleming, Buenos Aires, Argentina
Laura Torrecillas-Torres, Gastrointestinal Tumor Clinic, Centro Médico Nacional 20 de Noviembre, ISSSTE, Mexico City, Mexico
Francisco Alvarado, Department of Medical Affairs, Merck S.A., Guatemala
Cecilia Colombero, Department of Medical Affairs, Merck S.A., Buenos Aires, Argentina
Andre Sasse, Medical Management, Radium Instituto de Oncología, Campinas, Sao Paulo, Brazil


Objective: To describe the use of biomarker testing and therapy options for RASwt patients with metastatic colorectal cancer (mCRC) in Argentina, Brazil, and Mexico during the 2017-2019 period. Methods: We conducted descriptive analysis using datasets from privately-owned research tools. Results: There was an increase in the use of tests performed for RAS, BRAF and MSI in all three countries. Between 2018 and 2019, RAS testing increased 15% in Argentina, 29% in Brazil and 3% in Mexico. MSI testing increased 18% in Argentina and 19% in Brazil but remained stable in Mexico at 12%. BRAF testing increased 45% in Brazil, in Argentina 46% and 29% in Mexico. Main first-line available options for mCRC were: Chemotherapy (CT), CT+ (EGFR inhibitor/anti-VEGF). Conclusions: Given the paucity of publicly available information on access to mCRC treatments in Latin America, findings from this private data-based study may be useful for decision-making processes among healthcare institutions.



Keywords: Metastatic colorectal cancer. Biomarkers. RAS wild type. Target therapy. Latin America.